Background: Human epidermal growth factor receptor 2 (HER2) is related to the pathogenesis and poor outcome of numerous types of carcinomas, including gastric carcinoma. Gastric cancer patients with HER2 positivity have become potential candidates for targeted therapy with trastuzumab. Methods: We investigated 208 gastric cancer specimens using immunohistochemistry (IHC), fluorescence in situ hybridization and dual in situ hybridization (ISH). We also investigated the concordance between IHC and ISH. The correlation between HER2 status and various clinicopathological findings was also investigated. Results: In total, 15.9% (33/208) and 24.5% (51/208) of gastric cancers showed HER2 gene amplification and protein overexpression, respectively. A high level of concordance between ISH and IHC analyses (91.3%, κ = 0.76) was found. A significant correlation between HER2 status and intestinal-type (p < .05) and differentiated carcinomas (p < .05) was also noted. The HER2 heterogeneity was high in gastric cancers; we found 68.8% phenotypic heterogeneity and 57.6% genotypic heterogeneity. Heterogeneity in HER2 protein expression and gene amplification showed a close association with diffuse histologic type and IHC 2+. Conclusions: HER2 protein overexpression and gene amplification were detected in 24.5% and 15.9% of gastric cancer specimens, respectively. Intestinal-type showed a higher level of HER2 protein overexpression and gene amplification than diffuse type. HER2 status also showed a significant relationship with well-and moderately-differentiated carcinomas. The ratio of phenotypic and genotypic heterogeneity of HER2 was high in gastric carcinomas and was associated with HER2 IHC 2+ and diffuse histologic type. Pathology and Translational Medicine 2017; 51: 396-402 https://doi.org/10.4132/jptm.2017.04.24 ▒ ORIGINAL ARTICLE ▒ According to global cancer statistics from 2012 (GLOBOCAN 2012), gastric cancer remains the fourth most frequent cause of cancer-related mortality in developing countries. 1 In Vietnam, the incidence of gastric cancer has been increasing in recent years and poor outcome was due to delayed diagnosis and advanced stage.
▒ ORIGINAL ARTICLE ▒ According to global cancer statistics from 2012 (GLOBOCAN 2012), gastric cancer remains the fourth most frequent cause of cancer-related mortality in developing countries. 1 In Vietnam, the incidence of gastric cancer has been increasing in recent years and poor outcome was due to delayed diagnosis and advanced stage.
Conventional chemotherapy has not been very beneficial for gastric cancer. Targeted therapeutics, especially human epidermal growth factor receptor 2 (HER2) inhibitors, have recently shown more advantages in treating late-stage gastric cancer. 2 The Trastuzumab for Gastric Cancer trial has proven the efficacy of humanized monoclonal antibody against HER2 protein, so-called trastuzumab, in the treatment of advanced gastric cancer or gastroesophageal junction cancer with HER2 positivity. 3 HER2 is a proto-oncogene encoded by ERBB2 on chromosome 17, also a member of the HER family. The intracellular domain of HER2, a membrane-bound receptor tyrosine kinase, is responsible for extracellular signal transmission to initiate cellular signaling pathways such as mitogen-activated protein kinase, phosphoinositide 3-kinase, phospholipase C, and protein kinase C, leading to cell proliferation, cell survival, angiogenesis, migration, and invasion. 4 HER2-positive status (protein overexpression and/or gene amplification) has been identified in several carcinomas, especially in breast cancer, where it has a frequency of 20%-25%, suggesting its prognostic and predictive value in this carcinoma. 5 On the other hand, in gastric cancer, the reported level of HER2 overexpression and amplification varies widely from 7%-27%, [6] [7] [8] [9] [10] and the prognostic value of HER2 status is not commonly accepted.
This study aimed to detect HER2 status including protein expression and gene amplification, as well as investigate HER2 heterogeneity and the concordance between two methods (immunohistochemistry [IHC] and in situ hybridization). We also investigated the relationship between HER2 status and clinicopathological findings.
MATERIALS AND METHODS

Patients and tissue specimens
For this study, we retrospectively enrolled 208 gastric cancer patients who underwent curative gastrectomy at the University Medical Center, Ho Chi Minh City, Vietnam, from January 2012 to June 2015. No patients had received preoperative radiation or chemotherapy. All surgical specimens were promptly fixed in 10% buffered formalin, no longer than 30 minutes after resection, and for a fixing time of 8-48 hours. Clinicopathological features were recorded including age, sex, histologic type by Lauren, tumor differentiation, depth of invasion, lymph node status, and lymphovascular invasion.
IHC staining
We performed IHC staining for HER2 on the automated slide stainer (BenchMark XT), using monoclonal antibody 4B5 (Ventana Medical System, Tucson, AZ, USA) following the manufacturer's procedures. We incubated 5-µm slices after antigen retrieval (10 mM citrate buffer at 98ºC for 40 minutes) with 4B5 for 30 minutes. Subsequently 3,3'-diaminobenzidine was added for visualization. The sections were stained with hematoxylin for counterstaining and then cover-slipped. Negative controls (omission of primary antibody) and positive controls (gastric cancer tissue with known IHC HER2 3+) were included in each staining run.
Evaluation of IHC results
Slides were scored by a pathologist following the scoring system of Hofmann et al. 6 The generally accepted cut-off definition for HER2 membranous positivity is 10% of the tumor cells. A score of 0 was defined as no reactivity or membrane staining in < 10% of the tumor cells. Faint membrane staining was defined as a score of 1+. Weak-to-moderate complete membrane staining was defined as a score of 2+, and moderate-to-strong complete membrane staining was defined as a score of 3+. Scores of 2+ and 3+ were defined as HER2 protein positive/over-expression. Phenotypic heterogeneity was defined as the proportion of tumor cells showing membranous staining in more than 10%, but less than 50% of tumor cells.
In situ hybridization
We performed in-situ hybridization (ISH) for 208 cases of gastric cancer using dual-color silver in situ hybridization (SISH) (28 cases randomly selected) and fluorescence in situ hybridization (FISH) (the remaining 180 cases).
Fluorescence in situ hybridization HER2 gene amplification was detected by FISH using a Pathvision HER2 DNA probe kit (Vysis Inc., Downers Grove, IL, USA) according to the manufacturer's instructions. We heated hybridization buffer, DNA probe, and purified water to 73°C for 5 minutes. Slides were dipped in a denaturing bath (70% formamide 2 × saline-sodium citrate [SSC]) for 5 minutes at 73°C, then dehydrated in increasing ethanol concentrations, and then covered with the probe mixture. We incubated all slides for 30 minutes at 42°C, then washed with 0.4 × SSC/0.3% NP-40 for 2 minutes, air-dried in darkness, counterstained with 4',6-diamidino-2-phenylindole (DAPI), and lastly covered with a cover-slip. The signals were visualized under fluorescence microscope (BX51, Olympus, Tokyo, Japan) and the images were captured and saved with Spectral Imaging software (Applied Spectral Imaging Inc., Carlsbad, CA, USA). HER2 gene expression is represented by discrete red signals or signal clusters and Chr17 as green signals.
Dual-color SISH
We performed automated SISH on the Ventana Benchmark XT platform (Ventana Medical Systems Inc.) following the manufacturer's protocols and using the INFORM HER2 DNA and Chromosome 17 probes. HER2 is identified by a dinitrophenyl (DNP) labeled probe and visualized utilizing ultraView SISH DNP Detection Kit. The Chr17 centromere is labeled with a digoxigenin (DIG) probe and detected using ultraView Red ISH DIG Detection Kit (Ventana Medical Systems Inc.). The signals were visualized under light microscopy (BX50, Olympus) in which HER2 expression appeared as discrete black signals (SISH) and Chr17 as red signals. The mean HER2/CEP17 ratio was calculated by counting signals in 20 tumor cells under high-power field (× 600).
Evaluation of FISH and dual SISH results
HER2 gene status was based on the ratio of HER2 gene copies and Chr17 copies in nuclei of tumor cells. HER2 gene status was defined as non-amplified if the HER2/Chr17 ratio was under 2.0 or amplified if the HER2/Chr17 ratio was 2.0 or more. If the HER2/CEP17 ratio was 1.8 or more but less than 2.0, 20 more tumor cells were investigated to determine the HER2 gene status. HER2 amplification was further sub-classified into low-level amplification (HER2/CEP17 ratio 2-5) and high-level amplification (HER2/CEP17 ratio ≥ 5).
Polysomy of chromosome 17 was set as more than 3 CEP17 signals per nuclei. Genotypic heterogeneity was defined by the existence of more than 5% but less than 50% of tumor cells with a HER2/CEP17 ratio higher than 2.0.
Statistical analysis
We used SPSS ver. 15 
RESULTS
Clinicopathological characteristics of patients
Patient age ranged widely from 30 to 81 years (median, 58.2 years). There was a higher number of male patients (n = 139) than female patients (n = 69), with a male/female ratio of 2:1. Clinicopathological features are noted in Table 1 .
Overexpression of HER2
HER2 protein expression in 208 gastric tissue samples was investigated by IHC staining (Fig. 1) . Of the 208 gastric carcinoma tissue samples, 148 (71.2%) were scored as 0, 9 (4.3%) scored as 1+, 23 (11.1%) scored as 2+, and 28 (13.4%) scored as 3+. In total, 24.5% were positive (51/208).
HER2 amplification
The amplification rate of the HER2 gene was 15.9% (33/208) in all gastric carcinoma tissue samples, with 29 cases detected by FISH and four cases detected by dual SISH (Fig. 2) . Of amplified cases, 27 cases (81.8%) showed low-level amplification (ratio HER2/CEP17, 2 to < 5) and only six cases (18.2%) showed a high ratio HER2/CEP17 (> 5). Polysomy of chromosome 17 was not found in any of the tissue samples.
The correlation between IHC and ISH in the surgical specimens is shown in Table 2 . A concordance between IHC and ISH results was seen in 190/208 (157 IHC 0/1+ not amplified, 6 IHC 2+ amplified, and 27 IHC 3+ amplified) with a rate of 91.3% (κ = 0.76). Six out of 23 IHC 2+ cases (26.1%) showed amplification and one out of 28 IHC 3+ cases (3.6%), which showed signet ring cell carcinoma, was not-amplified.
Correlation between clinicopathological findings and HER2 status
The clinicopathological differences were shown in gastric carcinoma with or without HER2 protein expression or HER2 gene amplification. The HER2 protein expression and HER2 gene amplification rates were 43.6% (34/78) and 29.5% (23/78) in intestinal type gastric carcinomas (p < .05). HER2 status was also related to good differentiation (p < .05). However, no significant correlation was found between HER2 status and other clinicopathological features including sex and age of the patients, depth of invasion, lymph node status, and lymphovascular invasion (Table 3) .
Intratumor heterogeneity of HER2
HER2 showed phenotypic heterogeneity (IHC expression) and genotypic heterogeneity (gene amplification) (Fig. 3) . Phenotypic heterogeneity was observed in 35 of 51 IHC cases (68.8%), in which 12 cases of 28 IHC 3+ cases (42.9%) and all 23 IHC 2+ cases (100%) demonstrated heterogeneity. Phenotypic heterogeneity of HER2 expression was higher in the diffuse type than in the intestinal type (75% vs 67.6%). Genotypic heterogeneity was observed in 19 of 33 ISH cases (57.6%). Genotypic heterogeneity was higher in diffuse-type than in intestinal-type cancers (66.7% vs 52.2%). 
DISCUSSION
We investigated HER2 protein overexpression and gene amplification in 208 surgical tissue samples of gastric carcinoma. HER2 protein positivity and HER2 gene amplification were observed in 24.5% and 15.9% of cases, respectively. While HER2 protein positivity in gastric carcinoma was reported from 11 to 24%, 6, 8, [11] [12] [13] HER2 gene amplification varied from 7% to 27%. [7] [8] [9] [10] This variation was attributed to an inconsistent HER2 IHC scoring system, different methodologies including antibody selection and/or random selection of patients. Moreover, the interpretation of IHC or ISH can be influenced by subjective factors such as the prompt fixing time after removal, the volume of formalin, and the duration of fixation. In this study, all gastric specimens were fixed no later than 30 minutes after removal in 10% buffered formalin for 8-48 hours.
In our study, we used the HER2 scoring system proposed by Hofmann et al., 6 showing a high level of concordance (91.3%) between IHC and ISH. A number of studies investigated the relationship between IHC and FISH in gastric cancer specimens A B and also reported a high level of concordance that varied from 86.9 to 93.5%. 3, 6 Our study also showed high concordance between IHC and ISH. We did not compare the concordance between dual SISH and FISH in this study. However, some studies have shown a high level of concordance between dual SISH and FISH, which ranged from 94.5% to 98.3%. 3, 9 In this study, we recognized that one of 28 HER2 IHC 3+ cases showed non-amplification, and it was signet ring cell carcinoma. HER2 status may be found in this rare histologic type of gastric cancer with a very low rate of positivity. The HER2 protein expression in signet ring cell carcinoma may be misinterpreted due to strong nuclear/cytoplasmic staining, which was observed in the IHC staining method. Therefore, ISH confirmation should be considered in signet ring cell carcinoma.
The higher positive rates of HER2 in intestinal-type compared to other types of gastric carcinoma have been widely reported and our results were similar. 8, 11, [13] [14] [15] [16] It was also reported that HER2 overexpression is related to well-and-moderately differentiated gastric cancer but not with tumor stage or the age and sex of gastric cancer patients. 13, 17, 18 On the other hand, the correlation of positive HER2 status with other clinicopathological factors, including age, sex, and TNM stage, remains controversial. It has been reported that a higher frequency of HER2 positivity is significantly correlated with older age, male gender, upper location of tumor, lymphatic or vascular invasion, higher T stage, lymph node metastasis, distant metastasis, and higher TNM stage. 8, 11, 15, [19] [20] [21] In our study, we demonstrated that there was no significant relationship between HER2 status and clinicopathological variables such as sex and age of the patients, depth of invasion, lymph node status and lymphovascular invasion.
Genotypic heterogeneity was defined by College of American Pathologists (CAP) in 2009 for breast cancers, in which the tumor showed at least 5% but fewer than 50% of nuclei with a HER2/ CEP17 ratio ≥ 2.0. 22 The 2013 American Society of Clinical Oncology/CAP HER2 guideline update 5 recommends using an IHC HER2 test to define areas of potential amplification. In gastric cancer, there are no guidelines for tumor heterogeneity assessment. Yang et al. 16 recognized 79.3% of cases with heterogeneous HER2 protein expression and 44.0% of cases with HER2 genetic heterogeneity. Our results also showed that frequency of phenotypic heterogeneity was higher than that of genotypic heterogeneity (68.8% vs 57.6%).
Kim et al. 11 found that heterogeneity was more prevalent in IHC 2+ cases than IHC 3+ cases (90.9% vs 40.9%). Nishida et al. 23 also reported that phenotypic heterogeneity was recognized in 63.5% of IHC 2+ cases, and in only 28.3% in IHC 3+ cases.
Our results are consistent with results from these studies, in which phenotypic heterogeneity and genotypic heterogeneity showed a higher rate in IHC 2+ cases than IHC 3+ cases.
Lee et al. 24 recognized that diffuse or mixed histological subtypes have a higher rate of heterogeneous HER2 expression. In our study, we also found that the diffuse type showed a higher rate of heterogeneity for HER2 expression or amplification than did the intestinal type. These results may be important for pathologists to consider when predicting HER2 heterogeneity in IHC and ISH results during routine histological examination.
In conclusion, our study demonstrates that HER2 protein expression and gene amplification were recognized in 24.5% and 15.9% of gastric cancer patients, respectively. Intestinal-type disease showed a higher rate of HER2 protein expression and gene amplification than diffuse type. HER2 status also showed a significant relationship with well and moderately differentiated carcinomas. The ratio of phenotypic and genotypic heterogeneity of HER2 was high in gastric carcinoma and related to HER2 IHC 2+ and diffuse histologic type.
